NovaBay Pharmaceuticals - NBY Total Debt to Capital

The share price of NovaBay Pharmaceuticals (NBY) visualized below demonstrates a total debt-to-equity ratio of 0.59. NovaBay Pharmaceuticals maintains a core staff of biochemists and is recruiting new sales representatives. The business is based on outsourcing the production of ophthalmological solutions through US partners in compliance with GMP. Revenue is generated through the sale of dermatological and ophthalmic products via pharmacies and prescription orders.

NovaBay (NBY): All Debt to Shareholders' Equity Ratio from 07/04/2022 to 04/18/2026

Analytical breakdowns and data insights for company NovaBay Pharmaceuticals, Inc. (NBY)

- share price and consensus valuation forecast:

Stock Price NovaBay Pharmaceuticals Inc.|NBY - Fair Value Consensus

- issuer market value details:

Market Capitalization NovaBay Pharmaceuticals|NBY - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share NovaBay Pharmaceuticals|NBY - Accounting Value of Company|Market Value to Book Value Ratio novabay.com|NBY - Cumulative Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

NBY - Company Net Income

Fundamental company valuation:NovaBay Pharmaceuticals, NBY

The total debt-to-equity ratio measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the balance sheet's resilience to rising interest rates. Analyzing the trend of the debt dependency ratio allows for an assessment of how low capital expenditures and stable cash flow from Avenova sales protect NovaBay Pharmaceuticals (NBY) from credit risks.

Competitors of NovaBay Pharmaceuticals